You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

Article info

Article menu

Download PDFPDF

Epidemiology
Original research
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

Authors

  • Ai Phuong Tran Department of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, AustraliaSt John of God Private Hospital, Murdoch, Western Australia, Australia PubMed articlesGoogle scholar articles
  • D.F Tassone The University of Melbourne, Melbourne, Victoria, AustraliaGastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • N S Ding The University of Melbourne, Melbourne, Victoria, AustraliaGastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Johannes Nossent Rheumatology Section, School of Medicine, University of Western Australia Faculty of Medicine Dentistry and Health Sciences, Crawley, Western Australia, AustraliaRheumatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ai Phuong Tran; ai.tran{at}research.uwa.edu.au
View Full Text

Citation

Tran AP, Tassone D, Ding NS, et al
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)
RMD Open 2023;9:e002871. doi: 10.1136/rmdopen-2022-002871

Publication history

  • Received November 16, 2022
  • Accepted February 1, 2023
  • First published March 2, 2023.
Online issue publication 
February 14, 2024

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.